[
  {
    "ts": null,
    "headline": "A Once-in-a-Decade Opportunity: 3 Magnificent Stocks Down Between 40% and 73% to Buy Right Now",
    "summary": "Zoetis (NYSE: ZTS) is a leading animal healthcare company offering over 300 medicines, vaccines, and other precision health products to care for companion animals and livestock globally.  Since its spin-off from Pfizer in 2013, Zoetis has delivered an annualized total return of 15%, demonstrating the market-beating potential of what might look like a steady-Eddie investment at first glance.  Following this decline, though, Zoetis now trades at a price-to-earnings (P/E) ratio of 27 -- its lowest mark in a decade.",
    "url": "https://finnhub.io/api/news?id=410e330802b0d0f65401e3cfe2e5d3154c65c183dec76401131e78a89ac82d9a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745073600,
      "headline": "A Once-in-a-Decade Opportunity: 3 Magnificent Stocks Down Between 40% and 73% to Buy Right Now",
      "id": 134002504,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Zoetis (NYSE: ZTS) is a leading animal healthcare company offering over 300 medicines, vaccines, and other precision health products to care for companion animals and livestock globally.  Since its spin-off from Pfizer in 2013, Zoetis has delivered an annualized total return of 15%, demonstrating the market-beating potential of what might look like a steady-Eddie investment at first glance.  Following this decline, though, Zoetis now trades at a price-to-earnings (P/E) ratio of 27 -- its lowest mark in a decade.",
      "url": "https://finnhub.io/api/news?id=410e330802b0d0f65401e3cfe2e5d3154c65c183dec76401131e78a89ac82d9a"
    }
  },
  {
    "ts": null,
    "headline": "3 Magnificent Stocks to Buy That Are Near 52-Week Lows",
    "summary": "It's been a tough start to 2025 for investors amid concerns regarding the strength of the U.S. economy and uncertainties over the effect of sweeping changes in trade policy under the Trump administration.  Zoetis (NYSE: ZTS) is a global leader in animal health, with an extensive portfolio of medicines, vaccines, and diagnostic products for livestock and pets.  The company's diversification, covering 17 products generating over $100 million in annual revenue, including several best-in-class treatments, underscores its appeal as an investment.",
    "url": "https://finnhub.io/api/news?id=1e4e9d0c44a3b9b308482597b3051652778f7689f6e3eeb8fb6a5d1f45d77fe5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745065800,
      "headline": "3 Magnificent Stocks to Buy That Are Near 52-Week Lows",
      "id": 134022912,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "It's been a tough start to 2025 for investors amid concerns regarding the strength of the U.S. economy and uncertainties over the effect of sweeping changes in trade policy under the Trump administration.  Zoetis (NYSE: ZTS) is a global leader in animal health, with an extensive portfolio of medicines, vaccines, and diagnostic products for livestock and pets.  The company's diversification, covering 17 products generating over $100 million in annual revenue, including several best-in-class treatments, underscores its appeal as an investment.",
      "url": "https://finnhub.io/api/news?id=1e4e9d0c44a3b9b308482597b3051652778f7689f6e3eeb8fb6a5d1f45d77fe5"
    }
  }
]